Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism OX40 inhibitors(Tumor necrosis factor receptor superfamily member 4 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 1 | AU | 11 Jul 2022 | |
Endometrial Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
Hepatocellular Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
Melanoma | Phase 1 | AU | 11 Jul 2022 | |
Nasopharyngeal Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | AU | 11 Jul 2022 | |
Small Cell Lung Cancer | Phase 1 | AU | 11 Jul 2022 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | AU | 11 Jul 2022 | |
Triple Negative Breast Cancer | Phase 1 | AU | 11 Jul 2022 | |
Neoplasms | Phase 1 | AU | 09 Mar 2022 |